Novartis’ MS Pill Trial Success Boosts Blockbuster Prospects
Novartis AG’s experimental multiple sclerosis pill succeeded in two late-stage trials, boosting its chances of becoming a new oral treatment for the chronic neurological disease.
By Fabienne Kinzelmann · Bloomberg
Novartis AG’s experimental multiple sclerosis pill succeeded in two late-stage trials, boosting its chances of becoming a new oral treatment for the chronic neurological disease.